L Raiteri1, E Luccini, C Romei, S Salvadori, G Calò. 1. Department of Experimental Medicine, Pharmacology and Toxicology Section, University of Genoa, Viale Cembrano 4, Genova 16148, Italy. lraiter@pharmatox.unige.it
Abstract
BACKGROUND AND PURPOSE: Neuropeptide S (NPS) is a recently identified neurotransmitter/neuromodulator able to increase arousal and wakefulness while decreasing anxiety-like behaviour. As several classical transmitters play a role in arousal and anxiety, we here investigated the possible presynaptic regulation of transmitter release by NPS. EXPERIMENTAL APPROACH: Synaptosomes purified from mouse frontal cortex were prelabelled with [(3)H]5-hydroxytryptamine (5-HT), noradrenaline, dopamine, choline, D-aspartate or GABA and depolarized in superfusion with 12-15 mmol.L(-1) KCl to evoke [(3)H]neurotransmitter exocytosis. NPS was added at different concentrations (0.001 to 100 nmol.L(-1)). KEY RESULTS: NPS behaved as an extremely potent inhibitor of the evoked overflow of [(3)H]5-HT and [(3)H]noradrenaline exhibiting EC50 values in the low picomolar range. The inhibitory action of NPS on [(3)H]5-HT release was mimicked by [Ala(2)]NPS that was, however, about 100-fold less potent than the natural peptide. NPS (up to 100 nmol.L(-1)) was unable to affect the depolarization-evoked overflow of [(3)H]D-aspartate and [(3)H]GABA. The neuropeptide only weakly reduced the overflow of [(3)H]dopamine and [(3)H]ACh when added at relatively high concentrations. CONCLUSIONS AND IMPLICATIONS: NPS, at low picomolar concentrations, can selectively inhibit the evoked release of 5-HT and noradrenaline in the frontal cortex by acting directly on 5-hydroxytryptaminergic and noradrenergic nerve terminals. These direct effects may explain only in part the unique behavioural activities of NPS, while an indirect involvement of other transmitters, especially of glutamate, must be considered.
BACKGROUND AND PURPOSE:Neuropeptide S (NPS) is a recently identified neurotransmitter/neuromodulator able to increase arousal and wakefulness while decreasing anxiety-like behaviour. As several classical transmitters play a role in arousal and anxiety, we here investigated the possible presynaptic regulation of transmitter release by NPS. EXPERIMENTAL APPROACH: Synaptosomes purified from mouse frontal cortex were prelabelled with [(3)H]5-hydroxytryptamine (5-HT), noradrenaline, dopamine, choline, D-aspartate or GABA and depolarized in superfusion with 12-15 mmol.L(-1) KCl to evoke [(3)H]neurotransmitter exocytosis. NPS was added at different concentrations (0.001 to 100 nmol.L(-1)). KEY RESULTS:NPS behaved as an extremely potent inhibitor of the evoked overflow of [(3)H]5-HT and [(3)H]noradrenaline exhibiting EC50 values in the low picomolar range. The inhibitory action of NPS on [(3)H]5-HT release was mimicked by [Ala(2)]NPS that was, however, about 100-fold less potent than the natural peptide. NPS (up to 100 nmol.L(-1)) was unable to affect the depolarization-evoked overflow of [(3)H]D-aspartate and [(3)H]GABA. The neuropeptide only weakly reduced the overflow of [(3)H]dopamine and [(3)H]ACh when added at relatively high concentrations. CONCLUSIONS AND IMPLICATIONS: NPS, at low picomolar concentrations, can selectively inhibit the evoked release of 5-HT and noradrenaline in the frontal cortex by acting directly on 5-hydroxytryptaminergic and noradrenergic nerve terminals. These direct effects may explain only in part the unique behavioural activities of NPS, while an indirect involvement of other transmitters, especially of glutamate, must be considered.
Authors: Kay Jüngling; Thomas Seidenbecher; Ludmila Sosulina; Jörg Lesting; Susan Sangha; Stewart D Clark; Naoe Okamura; Dee M Duangdao; Yan-Ling Xu; Rainer K Reinscheid; Hans-Christian Pape Journal: Neuron Date: 2008-07-31 Impact factor: 17.173
Authors: Nancy E Badia-Elder; Angela N Henderson; Megan L Bertholomey; Neil C Dodge; Robert B Stewart Journal: Alcohol Clin Exp Res Date: 2008-06-28 Impact factor: 3.455
Authors: Yan-Ling Xu; Rainer K Reinscheid; Salvador Huitron-Resendiz; Stewart D Clark; Zhiwei Wang; Steven H Lin; Fernando A Brucher; Joanne Zeng; Nga K Ly; Steven J Henriksen; Luis de Lecea; Olivier Civelli Journal: Neuron Date: 2004-08-19 Impact factor: 17.173
Authors: Wei Si; Leah Aluisio; Naoe Okamura; Stewart D Clark; Ian Fraser; Steven W Sutton; Pascal Bonaventure; Rainer K Reinscheid Journal: J Neurochem Date: 2010-08-30 Impact factor: 5.372
Authors: Michael Camilleri; Paula Carlson; Alan R Zinsmeister; Sanna McKinzie; Irene Busciglio; Duane Burton; Marco Zucchelli; Mauro D'Amato Journal: Gastroenterology Date: 2009-09-02 Impact factor: 22.682
Authors: Luca Botticelli; Emanuela Micioni Di Bonaventura; Massimo Ubaldi; Roberto Ciccocioppo; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura Journal: Pharmaceuticals (Basel) Date: 2021-03-26
Authors: M Scott Bowers; Luisa P Cacheaux; Srishti U Sahu; Mary E Schmidt; Joseph A Sennello; Katherine Leaderbrand; M Amin Khan; Roger A Kroes; Joseph R Moskal Journal: J Neurochem Date: 2019-10-16 Impact factor: 5.372